Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jul 7;11:641522. doi: 10.3389/fonc.2021.641522

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Zeng, Lu, Liu, Zhao, Zhang, Hu, Shi, Tu, Xiao, Xu and Huang

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

The mechanism of anti-HIFs overcoming sorafenib resistance in hepatocellular carcinoma. Continuous sorafenib treatment induce the dysregulation of HIF-1α and HIF-2α expression in hepatocellular carcinoma, promoting the transcription of multiple genes involved in proliferation, CSCs, metastasis, glycolysis, mitophagy, and angiogenesis. Causes hepatocellular carcinoma to develop resistance to sorafenib. Anti-HIFs could overcome this drug resistance. BNIP3, adenovirus E1B 19kDa-interacting protein 3; NIX, BNIP3-like protein X; MDR, multidrug resistance protein; AMPK, AMP-activated protein kinase; GULT-1, glucose transporter 1; HK2, hexokinase 2; LDHA, lactate dehydrogenase A; PDK1, pyruvate dehydrogenase kinase isoform 1; c-Myc, Myc proto-oncogene protein; TGF-α, transforming growth factor α; RIT1, Ras like without CAAX 1.